NCT/Study#
NCT04535557 /
MOBOCERTINIB-EAP
An expanded access protocol for mobocertinib in refractory Non-Small Cell Lung Cancer patients with EGFR exon20 insertion mutations
DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
NA
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
